Search

Emergent BioSolutions Inc

Closed

SectorHealthcare

5.89 -1.17

Overview

Share price change

24h

Current

Min

5.73

Max

6

Key metrics

By Trading Economics

Income

-187M

-180M

Sales

78M

234M

P/E

Sector Avg

8.634

57.366

EPS

0.6

Profit margin

-76.91

Employees

900

EBITDA

-205M

-156M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+67.5% upside

Dividends

By Acuity

Next Earnings

28 Oct 2026

Market Stats

By TradingEconomics

Market Cap

-112M

266M

Previous open

7.06

Previous close

5.89

News Sentiment

By Acuity

20%

80%

46 / 340 Healthcare

Emergent BioSolutions Inc Chart

Past performance is not a reliable indicator of future results.

Related News

27 Aug 2026, 20:07 UTC

News

Emergent BioSolutions Inc. is under investigation, following a $180.2 million net loss and reduced revenue guidance, contributing to a decline in shares today.

26 Aug 2026, 20:08 UTC

Emergent BioSolutions Inc shares are higher, reflecting strong upward momentum since Tuesday. The stock remains well above its 20-day moving average.

25 Aug 2026, 20:07 UTC

Emergent BioSolutions Inc shares are higher during Tuesday's session, continuing a strong advance since Monday's close amid easing Treasury yields and lower oil prices.

24 Aug 2026, 19:51 UTC

Emergent BioSolutions Inc shares are higher today, continuing a cumulative increase since Friday. The stock remains below its 20-day moving average.

21 Aug 2026, 19:51 UTC

Emergent BioSolutions Inc shares are higher today, continuing a steady upward trend since Thursday's close. No specific news was identified to explain the movement.

20 Aug 2026, 19:02 UTC

News

Emergent BioSolutions Inc faces scrutiny after a $191.3 million impairment charge and a reduced revenue outlook, contributing to a decline in shares.

19 Aug 2026, 19:52 UTC

Emergent BioSolutions Inc is trading higher during Wednesday's session, recovering from earlier lows and reflecting strength since Tuesday's close. No specific news was identified.

18 Aug 2026, 20:06 UTC

Emergent BioSolutions Inc shares are higher today, reflecting a broader market recovery. The stock remains below its 20-day moving average and prior month levels.

17 Aug 2026, 19:56 UTC

News

Emergent BioSolutions faces investigations over financial disclosures, including a $191.3 million impairment charge, contributing to lower shares amid declining investor confidence.

13 Aug 2026, 19:51 UTC

Macro Event

Emergent BioSolutions Inc shares are roughly flat as jobless claims rise to 209,000, exceeding expectations. The stock remains below its 20-day moving average.

12 Aug 2026, 19:26 UTC

Emergent BioSolutions Inc gains amid broader market optimism following inflation data. The stock reached a session high before slightly pulling back.

11 Aug 2026, 22:56 UTC

Emergent BioSolutions Inc shares are trading lower in after-market hours. No specific news was identified to explain the movement.

10 Aug 2026, 19:51 UTC

News

Emergent BioSolutions shares are trading lower as H.C. Wainwright reduced its price target to $10.00, citing concerns over performance and outlook amid competitive pressures.

7 Aug 2026, 23:26 UTC

Emergent BioSolutions Inc shares rose in after-market trading, amid positive market sentiment and notable gains in major tech stocks. No specific news was identified.

6 Aug 2026, 23:41 UTC

Emergent BioSolutions traded roughly flat after market hours, with no specific news identified. The stock has declined significantly over the past month.

5 Aug 2026, 22:51 UTC

News

Emergent BioSolutions shares are lower in after-market hours following a Q2 net loss of $180.2 million and reduced full-year sales guidance.

29 Jul 2026, 19:56 UTC

Emergent BioSolutions Inc shares are trading higher Wednesday, reflecting gains since Tuesday's close, despite earlier fluctuations and broader market pressures.

27 Jul 2026, 18:46 UTC

Emergent BioSolutions Inc shares are higher amid a broader market trend, despite pulling back from earlier session highs. Crude oil prices have significantly declined.

23 Jul 2026, 19:36 UTC

Emergent BioSolutions Inc shares are lower, reflecting broader market trends amid negative earnings from major technology companies like Tesla and Alphabet.

Peer Comparison

Price change

Emergent BioSolutions Inc Forecast

Price Target

By TipRanks

67.5% upside

12 Months Forecast

Average 10 USD  67.5%

High 10 USD

Low 10 USD

Based on 2 Wall Street analysts offering 12 month price targets forEmergent BioSolutions Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

2 ratings

1

Buy

0

Hold

1

Sell

Sentiment

By Acuity

46 / 340 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat